21 institutions hold shares in ARCA biopharma Inc. (ABIO), with 37.18k shares held by insiders accounting for 0.26% while institutional investors hold 5.79% of the company’s shares. The shares outstanding are 9.38M, and float is at 9.28M with Short Float at 6.00%. Institutions hold 5.78% of the Float.
The top institutional shareholder in the company is Blackrock Inc. with over 0.29 million shares valued at $1.15 million. The investor’s holdings represent 1.99% of the ABIO Shares outstanding. As of Dec 30, 2020, the second largest holder is Renaissance Technologies, LLC with 0.21 million shares valued at $0.82 million to account for 1.43% of the shares outstanding. The other top investors are Vanguard Group, Inc. (The) which holds 87619.0 shares representing 0.61% and valued at over $0.35 million, while Gsa Capital Partners Llp holds 0.32% of the shares totaling 46097.0 with a market value of $0.18 million.
ARCA biopharma Inc. (NASDAQ: ABIO) is -10.47% lower on its value in year-to-date trading and has touched a low of $3.20 and a high of $22.00 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The ABIO stock was last observed hovering at around $3.55 in the last trading session, with the day’s gains setting it 0.04% off its average median price target of $7.00 for the next 12 months. It is also 48.71% off the consensus price target high of $7.00 offered by 1 analysts, but current levels are 48.71% higher than the price target low of $7.00 for the same period.
Currently trading at $3.59, the stock is 1.57% and -9.73% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.3 million and changing 1.13% at the moment leaves the stock -22.45% off its SMA200. ABIO registered 3.76% gain for a year compared to 6-month loss of -10.25%. The firm has a 50-day simple moving average (SMA 50) of $3.7403 and a 200-day simple moving average (SMA200) of $4.1449.
The stock witnessed a 3.16% gain in the last 1 month and extending the period to 3 months gives it a -15.13%, and is 4.36% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.02% over the week and 4.77% over the month.
Distance from 52-week low is 12.19% and -83.68% from its 52-week high.
ARCA biopharma Inc. (ABIO) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for ARCA biopharma Inc. (ABIO) is a “Buy”. 1 analysts offering their recommendations for the stock, where 0 rate it as a Hold and 0 think it is a “Overweight”. 1 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
ARCA biopharma Inc. is expected to release its quarterly report on 08/11/2021 and quarterly earnings per share for the current quarter are estimated at $0.The EPS is expected to grow by 50.20% this year.
ARCA biopharma Inc. (ABIO) Insider Activity
A total of 1 insider transactions have happened at ARCA biopharma Inc. (ABIO) in the last six months, with sales accounting for 0 and purchases happening 1 times. The most recent transaction is an insider purchase by CONWAY ROBERT E, the company’s Chairman of the Board. SEC filings show that CONWAY ROBERT E bought 10,000 shares of the company’s common stock on Dec 18 at a price of $4.16 per share for a total of $41630.0. Following the purchase, the insider now owns 30000.0 shares.
ARCA biopharma Inc. disclosed in a document filed with the SEC on Sep 25 that CONWAY ROBERT E (Chairman of the Board) bought a total of 5,000 shares of the company’s common stock. The trade occurred on Sep 25 and was made at $4.28 per share for $21399.0. Following the transaction, the insider now directly holds 20000.0 shares of the ABIO stock.
Still, SEC filings show that on Sep 22, CONWAY ROBERT E (Chairman of the Board) acquired 3,056 shares at an average price of $4.66 for $14241.0. The insider now directly holds 15,000 shares of ARCA biopharma Inc. (ABIO).